Karyopharm Therapeutics Files 8-K
Ticker: KPTI · Form: 8-K · Filed: Jul 11, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Jul 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements
Related Tickers: KPTI
TL;DR
KPTI filed an 8-K on 7/11, check it for Reg FD and financial updates.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on July 11, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details the company's principal executive offices located at 85 Wells Avenue, Newton, Massachusetts.
Why It Matters
This filing provides important regulatory and financial updates for Karyopharm Therapeutics Inc., which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — This is a routine regulatory filing with no immediate material financial or operational news.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- July 11, 2025 (date) — Date of report
- 85 Wells Avenue, Newton, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is primarily to report under Regulation FD Disclosure and to include Financial Statements and Exhibits.
When was this 8-K filed?
The 8-K was filed on July 11, 2025.
What is Karyopharm Therapeutics Inc.'s principal executive office address?
The principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459.
What is the company's state of incorporation?
Karyopharm Therapeutics Inc. is incorporated in Delaware.
What is the company's IRS Employer Identification Number (EIN)?
The EIN for Karyopharm Therapeutics Inc. is 26-3931704.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 11, 2025 regarding Karyopharm Therapeutics Inc. (KPTI).